Search
Somatostatin
go.drugbank.com/drugs/DB09099ApprovedInvestigationalWithdrawn[DB00104] is a long-acting analogue of somatostatin that inhibits the release of a number of hormones, and is clinically used to relieve symptoms of uncommon gastroenteropancreatic endocrine tumours, as … Somatostatin is initially secreted as a 116 amino acid precursor, preprosomatostatin, which undergoes endoproteolytic cleavage to prosomastatin.
Betibeglogene autotemcel
go.drugbank.com/drugs/DB16900ApprovedInvestigationalBetibeglogene autotemcel is an autologous gene therapy that adds functional copies of the β-globin gene (β<sup>A-T87Q</sup>-globin) to hematopoietic stem cells in order to treat β-thalassemia. … [L42940] β-thalassemia is a condition caused by mutations in the β-globin gene (HBB) that leads to a significant decrease in the production of β-globin.
Synonyms: Autologous CD34+ cells encoding βA-T87Q-Globin geneThiocolchicoside
go.drugbank.com/drugs/DB11582InvestigationalThiocolchicoside is a semi-synthetic derivative of the colchicine, a natural anti-inflammatory glycoside which originates from the flower seeds of _Superba gloriosa_. … It is a muscle relaxant with anti-inflammatory and analgesic effects. It has potent convulsant activity and should not be administered to individuals prone to seizures.[L1663]
Etesevimab
go.drugbank.com/drugs/DB15897InvestigationalEtesevimab (LY-CoV016, also known as JS016) is a fully human and recombinant monoclonal antibody that targets the SARS-CoV-2 surface spike protein receptor binding domain.
Albinterferon Alfa-2B
go.drugbank.com/drugs/DB05396InvestigationalAlbumin-interferon alpha (Albuferon) is a novel, long-acting form of interferon alpha. … Human Genome Sciences is developing Albuferon as a potential treatment for chronic hepatitis C.
Sarecycline
go.drugbank.com/drugs/DB12035ApprovedInvestigationalSarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 … Subsequently, while a number of first line tetracycline therapies like doxycycline and minocycline do exist for treating acne vulgaris, sarecycline presents a new and innovative therapy choice because
Velpatasvir
go.drugbank.com/drugs/DB11613ApprovedInvestigationalVelpatasvir acts as a defective substrate for NS5A (Non-Structural Protein 5A), a non-enzymatic viral protein that plays a key role in Hepatitis C Virus replication, assembly, and modulation of host immune … a high barrier to resistance [L852].
Ulotaront
go.drugbank.com/drugs/DB15665InvestigationalSEP-363856 is a novel psychotropic drug being investigated for the treatment of schizophrenia. … Unlike other drugs used for this condition, SEP-363856 does not bind to the dopamine D2 receptors, but exerts actions on the trace amine–associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5
Cannabidiol
go.drugbank.com/drugs/DB09061ApprovedInvestigationalFrom a pharmacological perspective, Cannabis' (and CBD's) diverse receptor profile explains its potential application for such a wide variety of medical conditions. … It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body.
Efonidipine
go.drugbank.com/drugs/DB09235InvestigationalThe drug has been shown to block T-type in addition to L-type calcium channels [A7844, A32001]. It has also been studied in atherosclerosis and acute renal failure [A32001]. … Efonidipine is a calcium channel blocker of the _dihydropyridine class_, commercialized by Shionogi & Co. (Japan). Initially, it was marketed in 1995 under the trade name, _Landel_.